Literature DB >> 17028213

Immune responses of elk to initial and booster vaccinations with Brucella abortus strain RB51 or 19.

S C Olsen1, S J Fach, M V Palmer, R E Sacco, W C Stoffregen, W R Waters.   

Abstract

Previous studies have suggested that currently available brucellosis vaccines induce poor or no protection in elk (Cervus elaphus nelsoni). In this study, we characterized the immunologic responses of elk after initial or booster vaccination with Brucella abortus strains RB51 (SRB51) and 19 (S19). Elk were vaccinated with saline or 10(10) CFU of SRB51 or S19 (n=seven animals/treatment) and booster vaccinated with a similar dosage of the autologous vaccine at 65 weeks. Compared to nonvaccinates, elk vaccinated with SRB51 or S19 had greater (P<0.05) antibody responses to SRB51 or S19 after initial vaccination and after booster vaccination. Compared to nonvaccinated elk, greater (P<0.05) proliferative responses to autologous antigen after initial vaccination occurred at only a few sample times in SRB51 (6, 14, and 22 weeks) and S19 (22 weeks) treatment groups. In general, proliferative responses of vaccinates to nonautologous antigens did not differ (P>0.05) from the responses of nonvaccinated elk. Gamma interferon production in response to autologous or nonautologous Brucella antigens did not differ (P>0.05) between controls and vaccinates after booster vaccination. Flow cytometric techniques suggested that proliferation occurred more frequently in immunoglobulin M-positive cells, with differences between vaccination and control treatments in CD4+ and CD8+ subset proliferation detected only at 22 weeks after initial vaccination. After booster vaccination, one technique ([3H]thymidine incorporation) suggested that proliferative responses to SRB51 antigen, but not S19 antigen, were greater (P<0.05) in vaccinates compared to the responses of nonvaccinates. However, in general, flow cytometric and other techniques failed to detect significant anamnestic responses to autologous or nonautologous Brucella antigens in S19 or SRB51 vaccinates after booster vaccination. Although some cellular immune responses were detected after initial or booster vaccination of elk with SRB51 or S19, our data suggest that responses tend to be transient and much less robust than previously reported in SRB51-vaccinated cattle (Bos taurus) or bison (Bison bison). These data may explain why the vaccination of elk with S19 and SRB51 induces poor protection against brucellosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17028213      PMCID: PMC1595328          DOI: 10.1128/CVI.00213-06

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  23 in total

1.  Brucella abortus strain RB51 vaccination in elk. II. Failure of high dosage to prevent abortion.

Authors:  Terry J Kreeger; Walter E Cook; William H Edwards; Philip H Elzer; Steven C Olsen
Journal:  J Wildl Dis       Date:  2002-01       Impact factor: 1.535

Review 2.  Crossregulation between Th1 and Th2 cells.

Authors:  P A Morel; T B Oriss
Journal:  Crit Rev Immunol       Date:  1998       Impact factor: 2.214

3.  Development of an adult-like cell-mediated immune response in calves after early vaccination with Mycobacterium bovis bacillus Calmette-Guérin.

Authors:  B J Nonnecke; W R Waters; M R Foote; M V Palmer; B L Miller; T E Johnson; H B Perry; M A Fowler
Journal:  J Dairy Sci       Date:  2005-01       Impact factor: 4.034

4.  Interferon-gamma is crucial for surviving a Brucella abortus infection in both resistant C57BL/6 and susceptible BALB/c mice.

Authors:  E A Murphy; J Sathiyaseelan; M A Parent; B Zou; C L Baldwin
Journal:  Immunology       Date:  2001-08       Impact factor: 7.397

5.  Safety and efficacy of Brucella abortus strain RB51 vaccine in captive pregnant elk.

Authors:  T J Kreeger; M W Miller; M A Wild; P H Elzer; S C Olsen
Journal:  J Wildl Dis       Date:  2000-07       Impact factor: 1.535

6.  Effects of exogenous recombinant interleukin-12 on immune responses and protection against Brucella abortus in a murine model.

Authors:  I K Lee; S C Olsen; C A Bolin
Journal:  Can J Vet Res       Date:  2001-10       Impact factor: 1.310

Review 7.  Immune systems in developed and developing countries; implications for the design of vaccines that will work where BCG does not.

Authors:  Graham A W Rook; Keertan Dheda; Alimuddin Zumla
Journal:  Tuberculosis (Edinb)       Date:  2006-02-28       Impact factor: 3.131

8.  Immune responses of bison to ballistic or hand vaccination with Brucella abortus strain RB51.

Authors:  Steven C Olsen; Terry J Kreeger; Will Schultz
Journal:  J Wildl Dis       Date:  2002-10       Impact factor: 1.535

9.  Immune responses of elk to vaccination with Brucella abortus strain RB51.

Authors:  Steven C Olsen; Terry J Kreeger; Mitchell V Palmer
Journal:  J Wildl Dis       Date:  2002-10       Impact factor: 1.535

10.  Efficacy of calfhood vaccination with Brucella abortus strain RB51 in protecting bison against brucellosis.

Authors:  S C Olsen; A E Jensen; W C Stoffregen; M V Palmer
Journal:  Res Vet Sci       Date:  2003-02       Impact factor: 2.534

View more
  6 in total

1.  Immune responses and protection against experimental challenge after vaccination of bison with Brucella abortus strain RB51 or RB51 overexpressing superoxide dismutase and glycosyltransferase genes.

Authors:  S C Olsen; S M Boyle; G G Schurig; N N Sriranganathan
Journal:  Clin Vaccine Immunol       Date:  2009-01-28

2.  Progress in Brucella vaccine development.

Authors:  Xinghong Yang; Jerod A Skyberg; Ling Cao; Beata Clapp; Theresa Thornburg; David W Pascual
Journal:  Front Biol (Beijing)       Date:  2013-02-01

3.  Vaccination with Brucella abortus recombinant in vivo-induced antigens reduces bacterial load and promotes clearance in a mouse model for infection.

Authors:  Jake E Lowry; Dale D Isaak; Jack A Leonhardt; Giulia Vernati; Jessie C Pate; Gerard P Andrews
Journal:  PLoS One       Date:  2011-03-11       Impact factor: 3.240

4.  Vaccination of Elk (Cervus canadensis) with Brucella abortus Strain RB51 Overexpressing Superoxide Dismutase and Glycosyltransferase Genes Does Not Induce Adequate Protection against Experimental Brucella abortus Challenge.

Authors:  Pauline Nol; Steven C Olsen; Jack C Rhyan; Nammalwar Sriranganathan; Matthew P McCollum; Steven G Hennager; Alana A Pavuk; Phillip J Sprino; Stephen M Boyle; Randall J Berrier; Mo D Salman
Journal:  Front Cell Infect Microbiol       Date:  2016-02-10       Impact factor: 5.293

5.  Estimating Loss of Brucella Abortus Antibodies from Age-Specific Serological Data In Elk.

Authors:  J A Benavides; D Caillaud; B M Scurlock; E J Maichak; W H Edwards; P C Cross
Journal:  Ecohealth       Date:  2017-05-15       Impact factor: 3.184

6.  Brucella melitensis Rev.1 vaccination generates a higher shedding risk of the vaccine strain in Alpine ibex (Capra ibex) compared to the domestic goat (Capra hircus).

Authors:  Claire Ponsart; Mickaël Riou; Yann Locatelli; Isabelle Jacques; Alain Fadeau; Maryne Jay; Roland Simon; Ludivine Perrot; Luca Freddi; Sylvain Breton; Thierry Chaumeil; Barbara Blanc; Katia Ortiz; Colin Vion; Damien Rioult; Erwan Quéméré; Pierre Sarradin; Jean-Yves Chollet; Bruno Garin-Bastuji; Sophie Rossi
Journal:  Vet Res       Date:  2019-11-27       Impact factor: 3.683

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.